Frontier Pharma: Hematological Cancers Market Report 2016 - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies

Dublin, Sept. 26, 2016 -- Research and Markets has announced the addition of the "Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies" drug pipelines to their offering.

The report assesses first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 463 first-in-class products, representing 45.3% of the pipeline with a disclosed molecular target.

The first-in-class targets in the pipeline are numerous and varied in nature. Cancer immunotherapies are the most common, with a total of 128 across all stages of development, followed by the signal transduction group of targets. The most commercially successful targeted drugs in the market fall into these two categories, including Rituxan (a cancer immunotherapy) and Gleevec (a signal transducer). The other target families have much fewer first-in-class products, reflecting the strong interest in cancer immunotherapies and targets implicated in signal transduction.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin's lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative, targeted therapies.

Scope

The hematological cancers market is characterized by commercially successful therapies.
- Which classes of drug dominate the market?
- What additional benefits have newly approved therapies brought to the market?

The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.
- Which molecular targets appear most frequently in the pipeline?
- To what degree is the pipeline penetrated by first-in-class innovation?
- Which target families have the most first-in-class products?

First-in-class products differ substantially in their clinical potential, based on their alignment to disease-causing pathways.
- How well are first-in-class targets aligned to known disease-causing pathways?
- Which targets are specifically found in early-stage development?
- Which are the most promising first-in-class targets in early-stage development?

There have been 284 licensing deals and 238 co-development deals pertaining to hematological cancer products since 2006.
- Which territories show the most deal activity?
- What were the trends in deal completion by product stage of development?
- Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Key Topics Covered:

1 Tables & Figures

2 Executive Summary
2.1 Significant Unmet Needs Persist in Hematological Cancer Market
2.2 Large Hematological Cancer Pipeline Displays Strong Degree of Innovation
2.3 Leuekmia Displays Most Pipeline Activity among Hematological Cancer Indications

3 The Case for Innovation in Hematological Cancers
3.1 Growing Number of Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance

4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Epidemiology
4.3 Pathophysiology
4.4 Symptoms
4.5 Diagnosis
4.6 Prognosis and Survival
4.7 Treatment
4.8 Overview of Marketed Products

5 Assessment of Pipeline Product Innovation
5.1 Pipeline by Molecule Type, Phase and Therapeutic Target
5.2 Comparative Distribution of Programs between Hematological Cancer Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs

6 Hematological Cancer Pathophysiology and Innovation Alignment
6.1 The Complexity of Signaling Networks in the Oncology
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.3 First-in-Class Target Matrix Assessment

7 First-in-Class Target Evaluation
7.1 Pipeline Programs which Target Interleukin-7 Receptor
7.2 Pipeline Programs that Target Notch 2 and Notch 3
7.3 Pipeline Programs that Target Focal Adhesion Kinase
7.4 Pipeline Programs that Target Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1
7.5 Pipeline Programs that Target Interleukin-1 Receptor Accessory Protein
7.6 Pipeline Programs that Target HLA-DR
7.7 Pipeline Programs that Target L-Selectin
7.8 Pipeline Programs that Target Eukaryotic Translation Initiation Factor 4E

8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs Not Involved in Licensing or Co-Development Deals

9 Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/8xgnxv/frontier_pharma

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Pharmaceuticals, Oncology Drugs , Hematological Drugs